Overview
Single-center randomized trial in patients with pacing indication (AV block) after TAVI (transfemoral aortic valve implantation) and LVEF> 50%, that aims to study the percentage of patients who improve at 12 months in a combined clinical endpoint.
Description
There is currently no evidence of the best mode of definitive pacing after TAVI in patients with preserved systolic ventricular function and AV block. Through this study, investigators intend to elucidate the best post TAVI pacing strategy, comparing the effect of right apical pacing vs. physiological pacing on the evolution of both echocardiographic and clinical parameters.
Investigators will include 24 patients without ventricular dysfunction (LVEF> 50%) and with AV block pacing indication after TAVI.
Patients will be randomized to 2 types of pacing (parallel randomized trial): physiological or right ventricular pacing (conventional).
PHYS-TAVI trial will analyze the following parameters in the 2 groups: survival; NYHA class; distance in the 6-minute walking test; hospital admissions; left ventricular function; echocardiographic asynchrony (strain and flash septal); NTproBNP; and quality of life/symptoms with the Kansas City Cardiomyopathy Questionnaire test (KCCQ-12)
Clinical, and echocardiographic follow-up will be performed for 1 year.
Inclusion of 24 more patients to those already included in the context of PHYSTAVI I (NCT04482816). Exploratory trial.
Eligibility
Inclusion Criteria:
- Successful implantation of TAVI according to VARC-3 criteria.
- Indication of cardiac pacing due to AV block according to ESC Guidelines.
- LVEF> 50%.
- The patient must indicate their acceptance to participate in the study by signing an informed consent document.
Exclusion Criteria:
- Ventricular dysfunction: LVEF <50%.
- Transapical TAVI.
- Participating currently in a clinical investigation that includes an active treatment.
- Patients with left bundle branch block but without indication of pacing (AV block).
- Life expectancy <12 months.